



SSO 2027 Annual Meeting Abstract Submission Guidelines

KEY DATES

Abstract Submission Deadline: October 5, 2026, 11:59 PM (CST) (Placeholders for Late-Breaking Abstracts must be submitted by the October 5 deadline.)

Abstract Administrative Corrections/Revisions Deadline: November 1, 2026

Abstract Withdrawal Deadline: November 1, 2026

Abstract Notifications Sent: Mid November 2026

Late-Breaking Abstract Submission Deadline: December 1, 2026, 11:59 PM (CST)

Abstract Supplement Published: March 2027

ABSTRACT ELIGIBILITY AND REQUIREMENTS

As you prepare your submission to the Meeting, please make note of the following details:

Submission Types

Authors may submit their work under one of the following abstract categories:

- Abstract
- Late-Breaking Abstract
- Team Science
- Trial In Progress
- Video Abstract

Submission Tracks and Categories

Authors must select one category that best fits the subject of their abstract. The Scientific Program Committee seeks abstracts in the following categories:

- Breast

- Colorectal
- Endocrine/Head & Neck
- Hepato-pancreato-biliary
- Melanoma
- Peritoneal Surface Malignancies
- Quality Improvement/Clinical Outcomes
- Sarcoma
- Thoracic
- Upper Gastrointestinal (lips to ileocecal valve, including esophagus and stomach)
- Disparities in Surgical Oncologic Care

Submission Requirements

- **Character Limit**

Abstracts must not exceed **2,300 characters**, including the title and body. Spaces are not counted toward the limit. Most special characters will transfer correctly when copying from a word processor. A character palette is available for additional symbol input.

- **Title Formatting**

Use **sentence case** (capitalize only the first word and proper nouns). Avoid periods, all caps, all lowercases, and formatting tags. Titles will be automatically formatted for print.

Product or brand names are not allowed—use only generic names. Titles containing brand names will be disqualified.

- **Abstract Body**

The abstract must include the following clearly labeled sections:

- **Introduction:** 2–3 sentences outlining the study’s objectives.
- **Methods:** Brief description of the study design (e.g., retrospective chart review, prospective trial). Do not include detailed lab techniques or mention the institution.
- **Results:** This should comprise 50–66% of the abstract. Include key data necessary for evaluation. Abstracts stating “data will be presented” will be disqualified.
- **Conclusions:** 2–3 sentences summarizing the significance of the findings in relation to the objectives.

Please Note: All text will be automatically formatted in plain text. Any use of bold, italics, or color will be converted to plain text.

- **Learning Objectives**

Provide 2-3 learning objectives clearly stating what participants should be able to do after engaging with your presentation.

- **Table or Image**

You may upload **one table or one image**. This does **not** count toward the character limit and can be edited or removed until the submission deadline.

- **Category**

Select the **one category** that best aligns with your abstract content.

- **Authors**

Provide a complete list of all authors in the intended order of appearance. For each author, include their full name, email address, credentials, and institutional affiliation. If a presenting author is not specified, the submitting author will be designated as the presenter by default.

Any final revisions to the author list order or presenting author must be submitted to ssoannualmeeting@surgonc.org no later than **November 1, 2026**.

- **Disclosure, Release and IRB Approvals**

The primary author and/or presenting author must provide Presenter Release and IRB approval (if applicable).

If your abstract is accepted for an oral or video presentation, SSO requires the primary author and/or presenting author to disclose financial relationships with any ineligible companies from the past 24 months and acknowledge any related support. All co-authors must agree with the content of the abstract to be considered for presentation. Refer to the [Conflict-of-Interest Policy](#) and follow the instructions provided in the submission process. Disclosure details will be included with acceptance letters.

- **Administrative Corrections/Revisions**

Revisions permitted until the abstract submission deadline of October 5, 2026:

- All abstract edits
- Author additions or removals

Limited administrative and minor editorial corrections permitted until November 1, 2026:

- spelling, grammar, or formatting corrections
- corrections to author names, degrees, or affiliations
- author order adjustments

The abstract review period begins on October 9, 2026. **No substantive scientific revisions, including changes to data, results, analyses, or conclusions, will be permitted after October 5, 2026.**

The author list submitted by October 5, 2026, is considered final. New authors may not be added and authors may not be removed after the submission deadline.

Any administrative and minor editorial corrections must be submitted to ssoannualmeeting@surgonc.org by **November 1, 2026**.

- **Withdrawals**

Abstract withdrawal requests must be submitted to ssoannualmeeting@surgonc.org by **November 1, 2026**.

Withdrawals requested after November 1, 2026, **will not be permitted** except under extraordinary circumstances and at the discretion of SSO.

- **Awards**

Review award opportunities [here](#). If eligible, select the appropriate award(s) during submission. Winners will be notified by **January 2027**.

Team Science Submissions

These should highlight work that has been presented or published within 6–12 months prior to the SSO Annual Meeting. Submissions must include full citation of the prior presentation or publication.

Trial in Progress Submissions

Trials in progress submissions are to be ongoing and have not yet reached pre-specified endpoints for analysis. As such, inclusion of results is prohibited, and abstracts with results, including secondary endpoints like toxicity or PROs, will not be considered for this session.

Abstracts submissions should include the following:

- **Background**
 - Scientific background/rationale for the trial
 - Preclinical and/or earlier-phase clinical data that has already been publicly presented or published may be included with references.
 - Correlative studies of relevance
- **Methods**
 - Trial design and statistical methods, highlighting any novel aspects of the design
 - Treatment or intervention planned
 - Major eligibility criteria, highlighting unusual aspects
 - Current enrollment without providing results or endpoints
 - **Enrollment must have already begun or completed with no data analysis available by the meeting date.** It is acceptable if the trial is open to enrollment but has not yet enrolled its first patient.
 - **Clinical trial registry number (required)**

Trial-in-Progress abstracts must be submitted by **October 5, 2026, at 11:59 PM CST**. No extensions will be granted.

Video Submissions

Are video abstract submissions accepted?

Yes. The SSO welcomes video abstracts that demonstrate innovative surgical techniques, unique or complex cases, and new therapies for specific disease sites. **Case Reports** are eligible for video submission. However, **promotional content**, whether personal or commercial, **will not be considered**.

Video abstracts selected for presentation will be evaluated based on scientific merit, educational value, technical quality, and clarity of presentation.

How to Submit a Video Abstract:

1. Submit an Abstract and Video

Complete your abstract submission following standard guidelines by the abstract submission deadline of October 5, 2026. Under “Abstract Submission Type,” select Video Abstract.

2. Complete All Submission Steps & Upload Video

Follow all required steps in the abstract submission system and upload the completed narrated video file when prompted. Submitted videos will be included in the peer review process. **Please note:** The uploaded video must not contain any identifying information (e.g., author names, institutions, or affiliations), as all submissions undergo a blinded peer-review process.

3. Presentation Format

Accepted videos will be presented using the submitted narrated video format. Presenting authors are expected to attend the session in person to participate in live discussion and audience Q&A.

Authors of accepted video abstracts may be required to upload a final presentation-quality video file prior to the Annual Meeting. A higher-quality version of the originally submitted video may be uploaded at that time; however, **final uploads may include technical or editorial updates only. Substantive scientific or operative content changes are not permitted.**

4. Video Requirements

- Maximum video length: 7 minutes
- File size limit: 2 GB
- Minimum resolution: 640 x 480 or 720 x 820 pixels (full screen)
- Submitted videos, **if accepted**, become the intellectual property of SSO.

Late-Breaking Submissions

The SSO late-breaking policy allows for the submission of late-breaking data only for the following:

- You must select the “late breaking” abstract type when submitting your abstract.
- Randomized phase II and III trials with no preliminary data available at the time of the abstract submission deadline (October 5, 2026).
- Original research studies highlight novel and high-impact research with practice-changing implications.

A placeholder (shell) abstract must be submitted by **October 5, 2026**. This must include:

- Background and Methods
- Primary clinical endpoint
- Provide a timeline for data analysis (Type and date of planned analysis)
- Planned statistical methods

Final late-breaking data must be submitted by December 1, 2026, at 11:59 PM CST and must include:

- Results and Conclusions sections.

SSO will send an email requesting final data. **Failure to submit by the deadline will result in abstract removal. No extensions will be granted.**

Review of late-breaking abstracts will begin on December 2, 2026, and conclude on December 8, 2026, at 11:59 PM CST. Notifications will be sent by mid-December 2026.

SSO Copyright Policy for Abstract Submissions

By submitting an abstract to the Society of Surgical Oncology (SSO), you acknowledge and agree to the following:

- You affirm that the submitted abstract and any resulting presentation are your **original work**.
- If your abstract is accepted, you grant SSO the right to use all related materials for **educational and promotional purposes**. This may include, but is not limited to:
 - **Recording and distributing** your oral presentation
 - **Publishing** your abstract or excerpts in print and/or digital formats
 - **Selling recordings** of the presentation as part of SSO's educational resources
- You confirm that you **own or control all rights** to the abstract and presentation and have the legal authority to assign those rights.
- Upon acceptance, you agree to **assign to SSO all copyrights** in your abstract and presentation materials, in any medium.

If you have questions about this policy or your rights, please contact the SSO Meetings Team at ssoannualmeeting@surgonc.org.

Presentation/Publication Prior to the SSO Annual Meeting

An abstract that has been or will be presented or published at another meeting prior to SSO Annual Meeting can be submitted for presentation if it was submitted for presentation at:

- San Antonio Breast Cancer Symposium
- ASCO GI Cancers Symposium
- SSO ACT Meeting
- It is submitted to the SSO Annual Meeting in the **Team Science category** and meets the **Team Science criteria**.
- **Abstracts accepted, presented, or published at any NATIONAL or GLOBAL meetings (other than those mentioned above) prior to March 17, 2027, are not eligible for presentation at SSO 2027.**
- **SSO will not accept abstracts that represent previously reported studies**, except those submitted in the **Team Science category**.

Abstract Selection Process & Presentations

What happens after I submit my abstract?

Once the submission period closes, all abstracts undergo a **blind peer review** conducted by members of the following committees and work groups:

- SSO Scientific Program Committee
- Breast Disease Site Work Group
- Colorectal Disease Site Work Group
- Endocrine/Head & Neck Disease Site Work Group
- Gastrointestinal Disease Site Work Group
- Hepato-Pancreato-Biliary (HPB) Disease Site Work Group
- Melanoma Disease Site Work Group
- Peritoneal Surface Malignancy Disease Site Work Group
- Sarcoma Disease Site Work Group
- Quality Committee
- Education & Innovation Committee
- SPHERE Committee

The **Scientific Program Committee** is responsible for all final decisions regarding abstract acceptance, presentation format, and scheduling.

To ensure **unbiased, high-quality presentations** and compliance with CME accreditation standards, all reviewers, session planners, and invited faculty are required to **disclose relevant financial relationships** through the designated online system.

Abstract Acceptance Notification & Presentation Requirements

Submitters will receive email confirmations upon both the initiation and completion of their abstract submission.

If your abstract is **accepted for presentation at SSO 2027**, the presenting author will receive an official notification from the Scientific Program Committee **in mid-November 2026**.

Presentation Requirements

- If the presenting author is unable to attend in person, a replacement presenter may be designated.
 - Newly designated presenters must submit financial disclosure information to the SSO.

Meeting Attendance Requirement:

- Prior to submission, ensure that the **presenting author or a co-author will be available to attend the meeting** and present the work.
- All presenters of accepted abstracts are required to:
 - **Register for the meeting at their own expense**
 - Cover their own **travel and registration expenses**

If you have questions, please contact the SSO Meetings Team at ssoannualmeeting@surgonc.org.

Accepted Abstracts and SSO Journals

Can I submit my accepted abstract to *Annals of Surgical Oncology* or *Surgical Oncology Insight*?

Yes. SSO encourages all presenters to publish their research in its official journals:

- *Annals of Surgical Oncology (ASO)*
- *Surgical Oncology Insight (SOI)*

SSO leadership strongly supports the dissemination of Annual Meeting research through these publications. Details and submission instructions will be provided for accepted presenters. Below is a summary of submission pathways:

Best Papers

- The **top 20 abstracts** will be selected as “Best Papers.”
- Authors will be **invited to submit full manuscripts to ASO by the end of December**.
- These submissions will be considered for **publication** after the Annual Meeting.
- The peer review process typically takes **up to 8 weeks**.
- Invitation emails will include detailed deadlines and submission instructions directly from ASO.

Oral Abstracts (Podium Presentations)

- Authors are **strongly encouraged** to submit manuscripts to Annals of Surgical Oncology within **three months** following the meeting.

Poster Abstracts (Quick Shot Poster Presentations, Poster Park Showcase and ePosters)

- Authors of accepted posters are **strongly encouraged** to submit manuscripts to Surgical Oncology Insight (SOI) within **three months** of the meeting.

Global Partner Abstract Program

- Authors whose abstracts are accepted through the Global Partner Program are also **strongly encouraged** to submit manuscripts to SOI within **three months**.

Further Questions?

If you have questions about the SSO 2027 Abstract Submission process, please contact the SSO:

 **Phone:** 847-427-1400 (Monday–Friday, during business hours)

 **Email:** ssoannualmeeting@surgonc.org

We're here to help!